Agios Pharmaceuticals (AGIO) vs Mineralys Therapeutics (MLYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Agios Pharmaceuticals (AGIO) has outperformed Mineralys Therapeutics (MLYS) over the past year, losing 22.2% versus a loss of 41.3%. Mineralys Therapeutics is the larger company by market cap ($1.95 billion vs $1.90 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | MLYS |
|---|---|---|
| Share price | $31.80 | $22.06 |
| Market cap | $1.90B | $1.95B |
| 1-day change | +0.03% | -0.16% |
| YTD return | +16.79% | -39.13% |
| 1-year return | -22.22% | -41.34% |
| 5-year return | -31.31% | — |
| EPS (TTM) | $-7.03 | $-4.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $46.00 | $47.65 |
| 52-week low | $22.24 | $21.46 |
| Distance from 52-week high | -30.87% | -53.71% |
| Analyst consensus | buy | none |
| Avg. price target upside | +44.65% | +119.90% |
| Average volume | 1.05M | 1.03M |
| Shares outstanding | 59.70M | 88.41M |
| Employees | 539 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGIO has outperformed MLYS by 19.1 percentage points over the past year.
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
AGIO vs MLYS FAQ
Which is bigger, Agios Pharmaceuticals or Mineralys Therapeutics?
Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $1.95B compared with $1.90B for Agios Pharmaceuticals (AGIO).
Which stock has performed better over the past year, AGIO or MLYS?
AGIO returned -22.22% over the past 12 months, compared with -41.34% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Agios Pharmaceuticals and Mineralys Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.